Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 109
Filter
1.
Matern Child Health J ; 28(4): 601-608, 2024 Apr.
Article in English | MEDLINE | ID: mdl-37980311

ABSTRACT

PURPOSE: The aim of this study is to analyze obstetrical and reproductive health parameters in Lebanon from 2015 until 2018 in the setting of the Syrian refugee influx in order to evaluate potential risks and provide a management plan to improve outcomes. DESCRIPTION: Data from the Lebanese Ministry of Public Health (LMPH) on all obstetrical deliveries that occurred in Lebanon between 2015 and 2018 was screened and analyzed. Number and mode of delivery as well as maternal and neonatal outcomes were included. Joinpoint regression analysis was used for trends of selected parameters. Independent two-sample t-tests were used for comparisons. ASSESSMENT: Women of non-Lebanese nationality residing in Lebanon had a significantly greater number of total deliveries (p-value < 0.001), vaginal deliveries (p-value = 0.002), cesarean sections (p-value = 0.02). When looking at delivery trends from 2015 to 2018, Lebanese women had a significant decrease in total number of deliveries (p-value < 0.001) and vaginal deliveries (p-value < 0.001). CONCLUSION: Total number of deliveries and cesarean sections is on the rise in Lebanon. Cesarean section practice should be audited by the LMPH and the Lebanese Order of Physicians (LOP). Local and international agencies should prioritize the implementation and management of family planning facilities in refugee hosting countries.


Subject(s)
Cesarean Section , Refugees , Female , Humans , Infant, Newborn , Pregnancy , Delivery, Obstetric , Lebanon/epidemiology , Public Health
2.
Am J Perinatol ; 40(15): 1644-1650, 2023 11.
Article in English | MEDLINE | ID: mdl-34775581

ABSTRACT

OBJECTIVE: This study aimed to compare the effectiveness of sustained uterine compression versus uterine massage in reducing blood loos after a vaginal delivery. STUDY DESIGN: This was a prospective randomized trial conducted at the American University of Beirut Medical Center (AUBMC) between October 2015 and October 2017. Inclusion criteria were women with a singleton pregnancy at ≥36 weeks of gestation, with less than three previous deliveries, who were candidates for vaginal delivery. Participants were randomized into two groups, a sustained uterine compression group (group 1) and a uterine massage group (group 2). Incidence of postpartum hemorrhage (blood loss of ≥500 mL) was the primary outcome. We assumed that the incidence of postpartum hemorrhage at our institution is similar to previously published studies. A total of 545 women were required in each arm to detect a reduction from 9.6 to 4.8% in the primary outcome (50% reduction) with a one-sided α of 0.05 and a power of 80%. Factoring in a 10% dropout rate. Secondary outcomes were admission to intensive care unit (ICU), postpartum complications, drop in hemoglobin, duration of hospital stay, maternal pain, use of uterotonics, or of surgical procedure for postpartum hemorrhage. RESULTS: A total of 550 pregnant women were recruited, 273 in group 1 and 277 in group 2. There was no statistically significant difference in baseline characteristics between the two groups. Type of anesthesia, rate of episiotomy, lacerations, and mean birth weight were also equal between the groups. Incidence of the primary outcome was not different between the two groups (group 1: 15.5%, group 2: 15.4%; p = 0.98). There was no statistically significant difference in any of the secondary outcomes between the two groups, including drop in hemoglobin (p = 0.79). CONCLUSION: There was no difference in blood loss between sustained uterine compression and uterine massage after vaginal delivery. KEY POINTS: · Transabdominal uterine compression and uterine massage are appropriate to prevent postpartum hemorrhage.. · No significant difference in blood loss or maternal discomfort observed between the two techniques.. · Both methods are equally effective and either one can be used based on provider preference..


Subject(s)
Postpartum Hemorrhage , Female , Pregnancy , Humans , Male , Postpartum Hemorrhage/prevention & control , Prospective Studies , Delivery, Obstetric/adverse effects , Massage/methods , Hemoglobins
3.
Mol Biol Rep ; 47(1): 169-177, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31595440

ABSTRACT

BACs-on-Beads (BoBs™) assay is a rapid aneuploidy test (RAT) that detects numerical chromosomal aneuploidies and multiple microdeletion/microduplication syndromes. This study was conducted to appraise the usefulness of the BoB™ assay as a complementary diagnostic tool to conventional karyotyping for the rapid detection of chromosomal aneuploidies. A total of 485 prenatal (amniotic fluid and chorionic villi) and blood/products of conception samples were collected between July 2013 and August 2018, and analyzed by the BoBs™ assay and cytogenetic karyotyping and further validated by fluorescence in situ hybridization (FISH). Forty-three of 484 qualifying samples (8.9%) were identified as abnormal by the BoBs™ assay. The assay was comparable to karyotyping in the detection of common structural abnormalities (trisomy 21, trisomy 18, X, and Y), with a sensitivity of 96.0% and a specificity of 100%. BoBs™ assay detected 20 microdeletion and microduplication syndromes that were missed by karyotyping. BoBs™, however, missed 10 cases of polyploidies and chromosomal rearrangements which were identified by conventional karyotyping. Our findings suggest that BoBs™ is a reliable RAT which is suitable in combination with conventional karyotyping for the detection of common aneuploidies. The assay also improves the diagnostic yield by recognizing clinically relevant submicroscopic copy number gains and losses.


Subject(s)
Aneuploidy , Chromosomes, Artificial, Bacterial , Karyotyping/methods , Prenatal Diagnosis/methods , Adult , Amniotic Fluid/chemistry , Blood Chemical Analysis/methods , Female , Humans , In Situ Hybridization, Fluorescence , Maternal Serum Screening Tests/methods , Microspheres , Pregnancy , Reproducibility of Results , Sensitivity and Specificity , Time Factors
4.
J Cancer Educ ; 34(1): 194-200, 2019 02.
Article in English | MEDLINE | ID: mdl-29019167

ABSTRACT

Clinical breast examination (CBE) is traditionally taught to third-year medical students using a lecture and a tabletop breast model. The opportunity to clinically practice CBE depends on patient availability and willingness to be examined by students, especially in culturally sensitive environments. We propose the use of a hybrid simulation model consisting of a standardized patient (SP) wearing a silicone breast simulator jacket and hypothesize that this, compared to traditional teaching methods, would result in improved learning. Consenting third-year medical students (N = 82) at a university-affiliated tertiary care center were cluster-randomized into two groups: hybrid simulation (breast jacket + SP) and control (tabletop breast model). Students received the standard lecture by instructors blinded to the randomization, followed by randomization group-based learning and practice sessions. Two weeks later, participants were assessed in an Objective Structured Clinical Examination (OSCE), which included three stations with SPs blinded to the intervention. The SPs graded the students on CBE completeness, and students completed a self-assessment of their performance and confidence during the examination. CBE completeness scores did not differ between the two groups (p = 0.889). Hybrid simulation improved lesion identification grades (p < 0.001) without increasing false positives. Hybrid simulation relieved the fear of missing a lesion on CBE (p = 0.043) and increased satisfaction with the teaching method among students (p = 0.002). As a novel educational tool, hybrid simulation improves the sensitivity of CBE performed by medical students without affecting its specificity. Hybrid simulation may play a role in increasing the confidence of medical students during CBE.


Subject(s)
Breast Diseases/diagnosis , Clinical Competence , Education, Medical, Undergraduate/methods , Educational Measurement/methods , Patient Simulation , Physical Examination/methods , Simulation Training/methods , Case-Control Studies , Female , Humans , Male , Middle Aged , Students, Medical/statistics & numerical data , Teaching
5.
Am J Perinatol ; 34(4): 379-387, 2017 03.
Article in English | MEDLINE | ID: mdl-27588932

ABSTRACT

Objective The objective of this study was to determine the optimal dose of intravenous oxytocin administered during cesarean delivery (CD) to decrease the amount of blood loss. Methods Out of a total of 226 women presenting for CD, 189 patients were randomized into three groups by a computer-generated random number sequence table. Low-risk women with singleton term pregnancies undergoing scheduled CD were assigned to receive 20, 30, or 40 units (U) of oxytocin diluted in 500 mL of lactated Ringer solution intraoperatively. The primary outcome was the change in hemoglobin from pre-CD to post-CD. Results Overall, 63 women were assigned to each group. The primary outcome which was the drop in hemoglobin (1.4 ± 1.1 g/dL, 1.1 ± 0.8 g/dL, 1.0 ± 1.1 g/dL; p = 0.097) and the total calculated blood loss (798.6 ± 298.3 mL, 794.4 ± 313.5 mL, 820.2 ± 316.2 mL; p = 0.893) were not significantly different among the study groups. The incidence of intraoperative hypotension, postoperative systolic, and diastolic blood pressure changes was similar across the groups. Conclusion The amount of blood loss during CD was not significantly different among the three groups, thus the lowest dose of oxytocin infusion (20 U in 500 mL of lactated Ringer solution) seems to be an appropriate regimen.


Subject(s)
Blood Loss, Surgical/prevention & control , Cesarean Section/adverse effects , Intraoperative Complications/prevention & control , Oxytocics/administration & dosage , Oxytocin/administration & dosage , Administration, Intravenous , Adult , Blood Pressure , Blood Volume , Double-Blind Method , Female , Hemoglobins/metabolism , Humans , Hypotension/etiology , Intraoperative Complications/etiology , Postoperative Period , Pregnancy
6.
BMC Pregnancy Childbirth ; 16: 96, 2016 Apr 30.
Article in English | MEDLINE | ID: mdl-27138281

ABSTRACT

BACKGROUND: Stress fractures are classified as insufficiency and fatigue fractures. Insufficiency fractures occur when normal stresses are placed on bone with decreased mineralization and elastic resistance; whereas fatigue fractures occur when abnormal forces are applied to normal bone. CASE PRESENTATION: We report a case of postpartum bilateral sacral fracture in the absence of documented osteoporosis in a 30 year old Lebanese female, thus satisfying the classification of fatigue fractures. Clinical presentation was mainly low back pain, pelvic pain, and abnormal gait. CONCLUSIONS: This case stresses the importance of including sacral fractures in the differential diagnosis of patients presenting with similar symptoms during pregnancy or the postpartum period.


Subject(s)
Fractures, Stress/diagnosis , Postpartum Period , Sacrum/injuries , Adult , Diagnosis, Differential , Female , Fractures, Stress/complications , Humans , Low Back Pain/etiology , Pregnancy
7.
Am J Perinatol ; 32(5): 417-26, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25535931

ABSTRACT

OBJECTIVE: This narrative review of the literature explores the current evidence and recommendations in favor of antenatal corticosteroids use during impending preterm deliveries as well as related issues and concerns. STUDY DESIGN: Synthesis of findings from published medical literature on antenatal corticosteroids and prematurity, retrieved from searches of computerized databases and authoritative texts. RESULTS: It is now recognized that an intramuscular course of betamethasone or dexamethasone given to a woman expected to deliver preterm not only accelerates pulmonary epithelial development but also matures other organ systems, significantly decreasing the chances of neonatal morbidities and increasing chances of survival. CONCLUSION: There remain uncertainties over the efficacy of the established protocol in populations such as the very early preterm, the late preterm, and multiple gestations. Alternative regimens remain controversial because of fear of adverse effects and doubts regarding whether benefits outweigh risks.


Subject(s)
Betamethasone/administration & dosage , Dexamethasone/administration & dosage , Glucocorticoids/administration & dosage , Pregnancy Complications/prevention & control , Premature Birth/prevention & control , Respiratory Distress Syndrome, Newborn/drug therapy , Female , Fetal Organ Maturity/drug effects , Gestational Age , Humans , Infant, Newborn , Infant, Premature/growth & development , Pregnancy , Randomized Controlled Trials as Topic
9.
Am J Perinatol ; 31(1): 1-8, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23359238

ABSTRACT

Intrahepatic cholestasis of pregnancy (ICP) has a varying prevalence worldwide. The etiology behind this disease remains not fully understood with multiple factors influencing its development including genetic variations, dietary factors, hormonal changes, and environmental influences. Presenting mainly during the third trimester with generalized itching and resolving spontaneously postpartum, this condition is still associated with fetal morbidity and mortality. The diagnosis is based on clinical presentation in association with biochemical abnormalities. Elevation in total bile acid levels is the most frequent laboratory abnormality and seems to be the most important for gauging further management of the disease. The most appropriate gestational age for the delivery of women with ICP is yet to be determined. In this review we discuss the epidemiology, clinical features, diagnosis, etiology, and management of ICP, trying to shed light on some controversial aspects of the disease.


Subject(s)
Cholestasis, Intrahepatic , Pregnancy Complications , Cholagogues and Choleretics/therapeutic use , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/etiology , Cholestasis, Intrahepatic/therapy , Female , Fetal Death/etiology , Fetal Distress/etiology , Fetal Monitoring , Gestational Age , Humans , Pregnancy , Pregnancy Complications/diagnosis , Pregnancy Complications/genetics , Pregnancy Complications/therapy , Premature Birth/etiology , Ursodeoxycholic Acid/therapeutic use
10.
Surg Technol Int ; 25: 195-200, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25433229

ABSTRACT

Multiple gestations are on the rise with the advent of artificial reproductive technologies. Even with ovulation induction using clomiphene citrate alone, the twinning rate can reach up to 9 percent. We report a case of recurrent twin gestation after treatment with clomiphene citrate, with the second pregnancy being heterotopic. We also review, using Medline and PubMed, previously reported cases of recurrent twin gestation after treatment with clomiphene citrate published before June 2014. Patients undergoing ovulation induction for oligoovulation, anovulation, or unexplained infertility should always be counseled about the possibility of multiple gestation prior to the treatment including the probability, although low, of a heterotopic pregnancy.

11.
Int J Gynaecol Obstet ; 162(1): 18-23, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37283471

ABSTRACT

The evidence indicates that pregnancy is associated with increased severity of some infectious diseases. Given the high maternal morbidity associated with influenza in pregnancy and the high neonatal morbidity and mortality associated with pertussis, the traditionally two recommended vaccines during pregnancy were those against influenza and Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccines. The recent COVID-19 pandemic introduced a third vaccine that after much debate is now recommended for all pregnant women. Other vaccines can be offered based for high-risk pregnant women, and only when the benefits of receiving them outweigh the risks. The soon expected vaccines against group B streptococcus infection and respiratory syncytial virus infection will be a breakthrough in reducing perinatal mortality. In this paper, the recommendations for administration of each vaccine during pregnancy are discussed.


Subject(s)
COVID-19 , Diphtheria-Tetanus-acellular Pertussis Vaccines , Influenza, Human , Tetanus , Whooping Cough , Infant, Newborn , Female , Pregnancy , Humans , Influenza, Human/prevention & control , Whooping Cough/prevention & control , Pandemics , COVID-19/prevention & control , Vaccination , Tetanus/prevention & control
12.
Acta Obstet Gynecol Scand ; 91(6): 658-78, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22375613

ABSTRACT

This article is a review of the literature assessing pregnancy outcomes and the effect of metformin treatment among women with polycystic ovary syndrome (PCOS). A review of research published in English was undertaken using PubMed and MEDLINE databases. The weight of the available evidence suggests that pregnant women with PCOS are at an increased risk of developing gestational diabetes, hypertensive disorders of pregnancy, preterm birth and early pregnancy loss. Obesity is a contributory factor for the increased risk of gestational diabetes in this group of women and is estimated to affect 5-40% of pregnant women with PCOS. The prevalence of other obstetric complications is estimated at 10-30% for gestational hypertension, 8-15% for pre-eclampsia and 6-15% for preterm birth. The association between PCOS and early pregnancy loss may not be direct, wherein the presence of PCOS-associated hyperinsulinemia, leading to hyperandrogenemia, has been implicated in the pathophysiology of early pregnancy loss. Apart from the role of metformin in improving the metabolic consequences accompanying PCOS, it has been shown to improve pregnancy rates in women with PCOS who are resistant to clomiphene citrate. In conclusion, pregnancy in women with PCOS is associated with adverse obstetric outcomes (multiple adverse obstetric risk). Whether metformin should be administered throughout pregnancy still remains controversial. Further prospective studies that foster a larger number of participants and adjust for all potentially confounding factors are needed.


Subject(s)
Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use , Polycystic Ovary Syndrome/drug therapy , Pregnancy Outcome , Abortion, Spontaneous/etiology , Abortion, Spontaneous/prevention & control , Diabetes, Gestational/etiology , Diabetes, Gestational/prevention & control , Female , Humans , Hyperandrogenism/drug therapy , Hyperandrogenism/etiology , Hyperinsulinism/drug therapy , Hyperinsulinism/etiology , Hypertension, Pregnancy-Induced/etiology , Hypertension, Pregnancy-Induced/prevention & control , Infertility, Female/etiology , Infertility, Female/therapy , Obesity/complications , Obesity/etiology , Polycystic Ovary Syndrome/complications , Pregnancy , Premature Birth/etiology , Premature Birth/prevention & control
13.
Acta Obstet Gynecol Scand ; 91(1): 117-121, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21615358

ABSTRACT

OBJECTIVE: To compare maternal and neonatal outcomes of twin gestations in nulliparous and multiparous women. DESIGN: Retrospective analysis of maternal and neonatal records. SETTING: American University of Beirut Medical Center, a referral university-affiliated hospital. POPULATION: Pregnant women who delivered twin gestations beyond 24 weeks from 1990 to 2004. METHODS: The data collected were analyzed using Student's paired t-test or χ(2) test. Logistic regression analysis was used to study the effect of multiple variables on preterm delivery. MAIN OUTCOME MEASURE: Preterm birth rate. RESULTS: Nulliparas (n=333) were more likely to be younger (28.1±5.4 vs. 30.0±5.2 years; p<0.001) and the pregnancy a product of assisted reproductive technology (23.1 vs. 4.5%; p<0.001) compared with multiparas (n=508). They were at significantly increased risk of preterm delivery (54.4 vs. 45.1%; p=0.009) at lower gestational age (35.6±3.2 vs. 36.2±3.0 weeks; p=0.004). They had longer first and second stages of labor and a higher cesarean delivery rate (61.3 vs. 44.9%; p<0.001). Except for a higher intensive care nursery admission rate and longer nursery stay for twins of nulliparas, all neonatal morbidities were comparable. On multiple logistic regression analysis, multiparity (relative risk 0.70, 95% confidence interval 0.51-0.97) and growth restriction (relative risk 0.16, 95% confidence interval 0.12-0.22) were protective, while discordance (relative risk 2.24, 95% confidence interval 1.40-3.60) was a predictor of preterm delivery. CONCLUSIONS: Nulliparous women with twin gestations are at significantly higher risk for preterm delivery and cesarean delivery compared with multiparous women. Although this was not translated into higher perinatal mortality, these women should be monitored closely and counseled regarding these risks and their attendant morbidity.


Subject(s)
Parity , Pregnancy Outcome , Pregnancy, Twin , Premature Birth/etiology , Adult , Cesarean Section/statistics & numerical data , Female , Gestational Age , Humans , Intensive Care Units, Neonatal , Labor, Obstetric , Logistic Models , Pregnancy , Pregnancy Complications/etiology , Retrospective Studies
14.
BMC Pregnancy Childbirth ; 12: 13, 2012 Mar 15.
Article in English | MEDLINE | ID: mdl-22420582

ABSTRACT

BACKGROUND: Preterm birth is the principal factor contributing to adverse outcomes in multiple pregnancies. Randomized controlled trials of progestogens to prevent preterm birth in twin pregnancies have shown no clear benefits. However, individual studies have not had sufficient power to evaluate potential benefits in women at particular high risk of early delivery (for example, women with a previous preterm birth or short cervix) or to determine adverse effects for rare outcomes such as intrauterine death. METHODS/DESIGN: We propose an individual participant data meta-analysis of high quality randomized, double-blind, placebo-controlled trials of progestogen treatment in women with a twin pregnancy. The primary outcome will be adverse perinatal outcome (a composite measure of perinatal mortality and significant neonatal morbidity). Missing data will be imputed within each original study, before data of the individual studies are pooled. The effects of 17-hydroxyprogesterone caproate or vaginal progesterone treatment in women with twin pregnancies will be estimated by means of a random effects log-binomial model. Analyses will be adjusted for variables used in stratified randomization as appropriate. Pre-specified subgroup analysis will be performed to explore the effect of progestogen treatment in high-risk groups. DISCUSSION: Combining individual patient data from different randomized trials has potential to provide valuable, clinically useful information regarding the benefits and potential harms of progestogens in women with twin pregnancy overall and in relevant subgroups.


Subject(s)
Pregnancy Complications/prevention & control , Pregnancy Outcome , Pregnancy, Twin/drug effects , Premature Birth/prevention & control , Progestins/therapeutic use , Adult , Clinical Protocols , Female , Humans , Infant, Newborn , Models, Statistical , Pregnancy , Randomized Controlled Trials as Topic
15.
Am J Perinatol ; 29(3): 175-86, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21786219

ABSTRACT

Preterm labor (PTL) is a major cause of neonatal morbidity and mortality worldwide. Among the available tocolytics, indomethacin, a prostaglandin synthetase inhibitor, has been in use since the 1970s. Recent studies have suggested that prostaglandin synthetase inhibitors are superior to other tocolytics in delaying delivery for 48 hours and 7 days. However, increased neonatal complications including oligohydramnios, renal failure, necrotizing enterocolitis, intraventricular hemorrhage, and closure of the patent ductus arteriosus have been reported with the use of indomethacin. Indomethacin has been also used in women with short cervices as well as in those with idiopathic polyhydramnios. This article describes the mechanism of action of indomethacin and its clinical applications as a tocolytic agent in women with PTL and cerclage and its use in the context of polyhydramnios. The fetal and neonatal side effects of this drug are also summarized and guidelines for its use are proposed.


Subject(s)
Fetus/drug effects , Indomethacin , Obstetric Labor, Premature/drug therapy , Polyhydramnios/drug therapy , Pregnancy Complications , Tocolytic Agents , Cerclage, Cervical , Cerebral Hemorrhage/chemically induced , Ductus Arteriosus/drug effects , Enterocolitis, Necrotizing/chemically induced , Female , Humans , Indomethacin/adverse effects , Indomethacin/pharmacology , Indomethacin/therapeutic use , Infant, Newborn , Infant, Premature, Diseases/chemically induced , Oligohydramnios/chemically induced , Pregnancy , Tocolytic Agents/adverse effects , Tocolytic Agents/pharmacology , Tocolytic Agents/therapeutic use
16.
Am J Perinatol ; 29(6): 429-34, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22399207

ABSTRACT

OBJECTIVE: To assess the effect of sildenafil citrate in a rat model of Nω-nitro-l-arginine methyl ester (L-NAME)-induced intrauterine growth restriction (IUGR). STUDY DESIGN: An in vivo experimental study was conducted where 40 pregnant Sprague-Dawley rats were randomly assigned to receive either: (1) control, (2) L-NAME 50 mg/kg/d by gavage (days 14 to 19), (3) L-NAME and sildenafil 15 mg/kg/d by gavage, or (4) sildenafil (days 14 to 21). On day 21, a hysterotomy was performed and all fetuses (live and dead) were counted, examined, and weighed. The primary outcome measure was the difference in pup birth weight. RESULTS: The median number of live pups per dam was 11.5 (range: 1 to 15), 13.5 (2 to 17), 13.5 (7 to 16), and 11.5 (4 to 17) in controls, L-NAME, sildenafil, and combined drug groups, respectively (p = 0.02). Rats treated with L-NAME had a significantly higher number of stillbirths compared with control (p = 0.013) and sildenafil (p = 0.008) groups. L-NAME reduced pup birth weight compared with controls (4.53 ± 1.49 versus 5.65 ± 1.63 g, p < 0.001); this effect was more pronounced in the L-NAME and sildenafil groups (3.37 ± 1.25 g, p < 0.001). CONCLUSION: Our data indicate that sildenafil citrate does not ameliorate L-NAME-induced IUGR, and in the doses utilized in this study might even have a synergistic negative effect on pup birth weight.


Subject(s)
Birth Weight/drug effects , Fetal Growth Retardation/prevention & control , Piperazines/pharmacology , Sulfones/pharmacology , Vasodilator Agents/pharmacology , Animals , Disease Models, Animal , Female , Fetal Growth Retardation/chemically induced , NG-Nitroarginine Methyl Ester , Piperazines/therapeutic use , Pre-Eclampsia/urine , Pregnancy , Proteinuria/chemically induced , Purines/pharmacology , Purines/therapeutic use , Rats , Rats, Sprague-Dawley , Sildenafil Citrate , Sulfones/therapeutic use , Vasodilator Agents/therapeutic use
17.
Surg Technol Int ; 22: 173-6, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23315718

ABSTRACT

We report the resection of a vaginal septum while preserving the virginity of a 12-year-old girl with Herlyn-Werner-Wunderlich Syndrome (HWWS) having a didelphys uterus, obstructed hemivagina, and an ipsilateral renal agenesis with follow-up at 18 months. Successful resection of the vaginal septum with conservation of the hymenal ring and complete drainage of both the hematocolpos and the hematometra were achieved. Cyclic dysmenorrhea and pelvic pain were completely resolved on follow-up visits at 4, 6, and 18 months. Office hysteroscopy performed during the last follow-up visit revealed a patent vaginal vault without evidence of adenosis or recurrence of the vaginal septum. Vaginoscopy is a safe, convenient, and efficient diagnostic and therapeutic modality that can be used in the management of patients with an obstructed hemivagina. It maintains the patient's virginity and it is useful in patients with a restrictive vaginal opening or narrow vaginal canal. Furthermore, the hysteroscopic excision of the vaginal septum offers minimal risk of recurrence of the septal defect.


Subject(s)
Abnormalities, Multiple/surgery , Endoscopy/methods , Plastic Surgery Procedures/methods , Uterus/abnormalities , Uterus/surgery , Vagina/abnormalities , Vagina/surgery , Abnormalities, Multiple/pathology , Child , Female , Gynecologic Surgical Procedures/methods , Humans , Uterus/pathology , Vagina/pathology
18.
J Matern Fetal Neonatal Med ; 35(18): 3453-3459, 2022 Sep.
Article in English | MEDLINE | ID: mdl-32954875

ABSTRACT

OBJECTIVES: To evaluate the practice patterns among Lebanese obstetricians regarding obstetric care of twins and to compare selected practice patterns between general obstetricians and maternal fetal medicine physicians. METHODS: Questionnaires distributed during the annual meeting of the Lebanese Society of Obstetrics and Gynecology. RESULTS: Questionnaires were returned by 69.2% of the 296 physicians approached. Ten percent had fellowship training in Maternal Fetal Medicine (MFM). Thirty-nine percent perform cervical length measurement at 20-24 weeks of gestation and 34% recommend vaginal progesterone in case of a short cervix. When comparing selected practice patterns between MFM & general obstetricians, MFM specialists were less likely to perform cervical cerclage in the first trimester (5.9% versus 49%, p = .001), more likely to offer prenatal screening for aneuploidy (66.6% vs 46.4%, p = .03), less likely to use vaginal progesterone in the second trimester in the case of a short cervix (42.1% vs 61.8%, p = .04), less likely to perform serial ultrasound exam in the third trimester to assess fetal growth (50% vs 78%, p = .005) and more likely to deliver monoamniotic twins at 32-34 weeks of gestation (55% vs 37%, p = .05). CONCLUSION: Because of the different background of the Lebanese physicians, MFM specialists are more likely to follow obstetric care guidelines in twin gestation.


Subject(s)
Gynecology , Obstetrics , Cervical Length Measurement , Female , Humans , Pregnancy , Pregnancy, Twin , Progesterone , Referral and Consultation
19.
Am J Perinatol ; 28(6): 449-60, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21170825

ABSTRACT

Preterm birth, the leading cause of neonatal morbidity and mortality, is estimated at incidence of 12.7% of all births, which has not decreased over the last four decades despite intensive antenatal care programs aimed at high-risk groups, the widespread use of tocolytics, and a series of other preventive and therapeutic interventions. Oxytocin antagonists, namely atosiban, represent an appealing choice that seems to be effective with apparently fewer side effects than the traditional tocolytics. This article reviews the available literature on the pharmacokinetics, mode of administration, and clinical utility of oxytocin antagonists for acute and maintenance tocolysis with special emphasis on its safety profile.


Subject(s)
Hormone Antagonists/therapeutic use , Oxytocin/antagonists & inhibitors , Premature Birth/prevention & control , Tocolytic Agents/therapeutic use , Vasotocin/analogs & derivatives , Female , Hormone Antagonists/administration & dosage , Hormone Antagonists/pharmacokinetics , Humans , Indoles/therapeutic use , Nifedipine/therapeutic use , Oligopeptides/therapeutic use , Pyrrolidines/therapeutic use , Sympathomimetics/therapeutic use , Tocolytic Agents/administration & dosage , Tocolytic Agents/pharmacokinetics , Vasotocin/administration & dosage , Vasotocin/pharmacokinetics , Vasotocin/therapeutic use
20.
Am J Perinatol ; 28(1): 57-66, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20640972

ABSTRACT

Preterm birth continues to be the leading cause of perinatal morbidity and mortality. A wide range of tocolytics have been utilized for the management of preterm labor. Calcium channel blockers, namely nifedipine, gained popularity as tocolytics due to the oral route of administration, availability of immediate- and slow-release preparations, the low incidence of maternal adverse effects associated with their use, and the fact that they are inexpensive. This article reviews the available literature on the clinical utility of calcium channel blockers for acute and maintenance tocolysis with special emphasis on potential adverse effects, the most appropriate dose/regimen, and contemporary practice patterns among obstetricians. There are no randomized, placebo-controlled studies demonstrating the benefit of nifedipine in preterm labor. A suggested tocolytic protocol would be to start with the lowest dose of oral immediate-release nifedipine. For the first 48 hours thereafter, all attempts should be made not to exceed 60-mg daily doses.


Subject(s)
Calcium Channel Blockers/adverse effects , Nifedipine/adverse effects , Obstetric Labor, Premature/drug therapy , Premature Birth/prevention & control , Tocolytic Agents/adverse effects , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/therapeutic use , Female , Humans , Nifedipine/administration & dosage , Nifedipine/therapeutic use , Practice Patterns, Physicians' , Pregnancy , Tocolytic Agents/administration & dosage , Tocolytic Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL